BOONTON, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE http://www.unigene.com) has completed a clinical study which suggests that its oral tablet formulation of calcitonin, based on its Enteripep® technology, may protect bone even more effectively if it is administered at night. The rate at which bone resorption (loss) occurs follows a diurnal rhythm, with the greatest bone loss occurring at night. The therapeutic benefit from an osteoporosis medication that reduces bone resorption would therefore be expected to be maximal with nighttime dosing. Unigene therefore conducted a small clinical study, using two different dosing regimens, which investigated the ability of nighttime calcitonin dosing to reduce the rate of bone resorption.
